



FY2007

(Fiscal Year Ending March 31, 2008)

Semiannual Financial Results Presentation



October 30, 2007







Safe Harbor Statement

• Materials and information provided during this presentation may contain socalled "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and





	1H FY	2006	1H FY2007				
	Results	%	Results	%	YOY (%)	Increase	
Net Sales	319.4	100.0	362.8	100.0	114	43.4	
Cost of Sales	53.2	16.7	54.6	15.0	103	1.4	
Gross Margin	266.2	83.3	308.2	85.0	116	42.1	
R&D Expenses	52.2	16.4	63.8	17.6	122	11.6	
SG&A Expenses	164.3	51.4	187.3	51.6	114	23.0	
Operating Income	49.6	15.5	57.1	15.7	115	7.4	
Ordinary Income	51.7	16.2	59.6	16.4	115	7.8	
Net Income	32.5	10.2	39.4	10.8	121	6.8	
EPS (yen)	113.8		138.5		122	24.7	
R&D Expenses + Operating Income	101.9	31.9	120.9	33 3	119	19.0	
	1		•		I	(





Sales to Customers by Geographic Area

(billion yen)

	1H FY2006		1H FY2007				
	Results	%	Results	%	YOY (%)	Increase	
Japan	143.5	44.9	157.4	43.4	110	13.9	
North America	139.1	43.6	164.2	45.3	118	25.1	
Europe	26.5	8.3	27.3	7.5	103	0.8	
Asia and Others	10.3	3.2	14.0	3.8	136	3.7	
Overseas Total	175.9	55.1	205.4	56.6	117	29.5	
Total	319.4	100.0	362.8	100.0	114	43.4	



Operating Income by Geographic Area

(billion yen)

	1H FY	′2006	1H FY2007				
	Results	%	Results	%	YOY (%)	Increase/ Decrease	
Japan	34.1	66.6	45.8	77.0	134	11.7	
North America	13.3	25.9	9.7	16.3	73	(3.5)	
Europe	2.0	3.9	0.9	1.5	44	(1.1)	
Asia and Others	1.8	3.6	3.1	5.2	169	1.3	
Overseas Total	17.1	33.4	13.7	23.0	80	(3.4)	
Sub Total	51.2	100.0	59.6	100.0	116	8.3	
Elimination/ Corporate	(1.6)		(2.5)			(0.9)	
Total	49.6		57.1		115	7.4	



Performance of Eisai Inc.



	1H FY	2006	1H FY2007				
	Results	%	Results	%	YOY (%)	Increase/ Decrease	
Net Revenue	1,212	100.0	1,392	100.0	115	180	
Aricept [®]	631	52.0	750	53.9	119	119	
AcipHex [®]	524	43.2	556	40.0	106	32	
Fragmin [®]	31	2.6	31	2.3	101	0	
4 Cancer products (ONTAK® and others)	-	1	23	1.6	-	23	
Operating Income	107	8.9	90	6.4	83	(18)	
Net Income	74	6.1	63	4.5	84	(12)	
Operating Income (Pre-royalty deduction)	288	23.8	348	25.0	121	60	






	Operating Cash Flows		·	pital ditures	Free Cash Flows		
	Results	Increase/ Decrease	Results	Increase/ Decrease	Results	Increase/ Decrease	
1H FY2003	45.8	26.3	9.8	(4.4)	36.0	30.7	
1H FY2004	40.8	(5.1)	24.2	14.3	16.6	(19.4)	
1H FY2005	39.9	(0.9)	19.2	(5.0)	20.7	4.1	
1H FY2006	36.6	(3.3)	14.2	(5.0)	22.4	1.7	
1H FY2007	41.7						









Investing for the Future (1)

E2007	Epilepsy, multiple sclerosis
E5555	Acute coronary syndrome
	Atherothrombotic disease
AS-3201	Diabetic complications
E7080	Cancer (VEGF receptor tyrosine kinase inhibitor)
E7974	Cancer (Tubulin polymerization inhibitor)
E3210	Irritable bowel syndrome
E2007	Migraine prophylaxis
MORAb-0	003 Ovarian cancer (MAb targeting
	folate receptor alpha
MORAb-0	009 Pancreatic cancer (MAb targeting
	mesothelin)
E7107	Cancer (RNA splicing modulator)
E3710	Acid-related diseases/New PPI
E6201	Psoriasis







Investing for the Future (3)



Acquisition of Morphotek®, Inc.

- Entering the biologics field with proprietary technologies in fully human antibodies, called Human MORPHODOMA® and LibradomaTM
- Collaborating with eminent U.S. research institutes for antibody drug research: Johns Hopkins, National Cancer Institute, Memorial Sloan-Kettering Cancer Center and others
- Strengthening discovery units and pursuing closer collaboration among Eisai's research laboratories
 - Tsukuba Laboratories (Japan)
 Eisai Research Institute of Boston (U.S.)
 - Eisai London Research Laboratories (UK) KAN Research Institutes (Japan)
 - Morphotek[®], Inc. (U.S.)
- Enriching antibody pipeline
 - 2 compounds in clinical stage (MORAb-003, MORAb-009)
 - 5 compounds in preclinical stage (MORAb-004, MORAb-022, MORAb-028, MORAb-047, MORAb-048)
- Received funding approvals from U.S. government agencies to support the development of MAb therapies as antidotes against biowarfare and infectious pathogenic agents
 - 1) Generating human MAbs to Botulinum toxins funded by U.S. Department of Defense (\$2.3 million)
 - 2) Generating human MAbs to neutralize the toxic effects of staphylococcus enterotoxin B funded by National Institute of Allergy and Infectious Diseases (NIAID) (\$2.7 million)





3. Investment in New Knowledge

♦ European Knowledge Center (EKC)

- Construction of EKC ongoing as planned at the 14.5 acre site in Hatfield, to the north of London
- Create knowledge by integrating functions including European headquarters, discovery research, clinical development, manufacturing and sales
- Total investment: approx. 100 million pounds
- Regional headquarters to begin first phase of operation in FY2008

♦Knowledge Creation in India

 Plan to hold a groundbreaking ceremony for Eisai Pharmatechnology & Manufacturing Pvt. Ltd in Vizag, India, knowledge creation center which includes API research and production facilities, formulation research and production facilities





Performance Forecast


(billion yen)

	FY2006		FY2007					
	Results	%	Forecast	%	YOY			
Net Sales	674.1	100.0	739.0	100.0	110			
Cost of Sales	109.3	16.2	110.5	15.0	101			
Gross Profit	564.8	83.8	628.5	85.0	111			
R&D Expenses	108.3	16.1	127.0	17.2	117			
SG&A Expenses	351.2	52.1	384.5	52.0	109			
Operating Income	105.3	15.6	117.0	15.8	111			
Ordinary Income	110.5	16.4	121.0	16.4	110			
Net Income	70.6	10.5	78.5	10.6	111			
EPS (yen)	247.8		275.5		111			
Dividend (yen)	120		130	interim div	vidend: 65			





Imbalance of CNS circuit Parkinson's disease **Epilepsy** Pain







E2007 (perampanel) AMPA receptor antagonist

Neuropathic Pain

- POC study ongoing for pain associated with diabetic neuropathy
- Study ongoing with 78 patients enrolled out of target 350, as of October 24, 2007
- Seek to achieve POC in FY2008 and to submit an NDA/MAA in FY2010

Epilepsy

- High-dose tolerability study ongoing (maximum 12 mg)
- Plan to have meetings with regulatory authorities to finalize Phase III study design

Japan

- Phase I study ongoing
- Plan to start Phase II study for Parkinson's disease and neuropathic pain



E2007 (perampanel)



AMPA receptor antagonist

(Fiscal year)

		2006	2007	2008	2009	2010	2011	2012
Parkinson's disease	U.S. and EU		study ongoing study ongoing	Submission				
	JP	Phase I study ongoing Submission Target						
Neuropathic pain	U.S. EU		Phase II st	udy ongoing		Submission Target		Submission
pani	JP		Phase I stud	dy ongoing				Target
Epilepsy	U.S. EU	Phase II POC a Tolerabili ongo	Phase ty study prepa	>				Submission Target
Migraine prophylaxis	U.S. EU		udy completed g high-dose stu					
Multiple sclerosis	U.S. EU			OC study paration				



E7389 (eribulin mesylate)



Microtubule Growth Suppressor

Breast cancer

- 3rd line Subpart H study in U.S. Completed pre-NDA meeting with FDA in August 2007 Target database lock and data analysis in November 2007 Considering a new drug was approved for 3rd line breast cancer, plan to conduct detailed analysis of data in order to further demonstrate the advantage of E7389 Changed NDA submission timing under Subpart H in U.S. from 3Q FY2007 to 4Q FY2007
- 3rd line, Phase III Enrollment ongoing for the EU submission in FY2009
- Designated as "Fast Track" for 3rd line breast cancer by U.S. FDA
- 2nd line, Phase III Enrollment ongoing for the U.S. and EU submission in FY2010
- Phase II in Japan Completed the meeting with MHLW in June 2007 and initiated Phase II study for breast cancer

Prostate cancer (Phase II POC study)

- Enrollment completed in June 2007, goal is to achieve POC by the end of FY2007

Sarcoma (Phase II POC study)

- Enrollment ongoing in EU

Non-small cell lung cancer (Phase lb/II in combination with carboplatin)


- Enrollment ongoing in U.S.





E7389 (eribulin mesylate)

Microtubule Growth Suppressor (Fiscal year)







E5564 (eritoran tetrasodium) Endotoxin Antagonist

Aim World's First TLR-4 Antagonist for the Treatment of Severe Sepsis

- Phase III study for severe sepsis ongoing
 - A global study to aim simultaneous filing in the U.S., Europe and Japan
 - Steady enrollment with 372 patients as of October 25, 2007
 - Initiated administration in Japan in October 2007
 - Accelerated site open in Asia
- Plan to submit NDAs simultaneously in the U.S., Europe and Japan in FY2009



E5555




Thrombin Receptor Antagonist

Atherothrombotic disease

- Initiated Phase II overseas
- Initiated Phase II in Japan
- Phase II study design:
 - CAD with high risk of cardiovascular events
 - Administration
 - Once a day, placebo, 50mg, 100mg, 200mg/day
 - Treatment 24 weeks, follow up 4 weeks
 - 600 patients
 - Efficacy endpoints
 - Major Adverse Cardiovascular Events (MACE)
 - Plasma levels of possible biomarkers

Acute coronary syndrome (ACS)

- Initiated Phase II overseas
- Initiated Phase II in Japan
- Phase II study design:
 - · Within 24 hours of the onset
 - Administration
 - Loading dose 400mg on Day 1, once a day
 - Placebo, 50mg, 100mg, 200mg/day
 - 600 patients
 - Efficacy endpoints
 - Major Adverse Cardiovascular Events (MACE)
 - ST-segment shifts during the first 48 hours following randomization
 - Plasma levels of possible biomarkers







AS-3201

Aldose Reductase Inhibitor

- Plan to initiate Phase II/III studies for diabetic neuropathy and diabetic retinopathy after consulting with the FDA
- Development strategy
 - Treatment/observation period
 - Due to slow progression of disease, long-term treatment will be necessary
 - Extend the treatment period
 - Patient population
 - Based on the mode of action, AS-3201 is expected to prevent worsening rather than to show quick improvement
 - Prevention of disease progression
 - Use validated clinical endpoints
 - » NIS-LL (diabetic neuropathy)
 - » ETDRS scale (diabetic retinopathy)



E2012



Gamma Secretase Modulator

Aim the World's First Disease Modifier in Alzheimer's disease area

Elucidation of "No Observed Adverse Effect Level" (NOAEL) for lenticular opacities in rats

- Single-dose administration does not result in lenticular opacities at the highest dose in rats (observed for 6 months after cessation of the drug)
- 13-week study to establish NOAEL for lenticular opacities ongoing
- Study to assess potential for recovery of lenticular opacities ongoing Aβ 42 is decreased within the range of NOAEL in rats

Examination of safety marker to be used in clinical studies

- Inhibition of cholesterol production might be relevant to the formation of lenticular opacities in rats
- Reduction in cholesterol in blood was observed at doses associated with lenticular opacities in rats
- Seek to confirm the safety marker which might be detected prior to the lowering of cholesterol in blood and lenticular opacities



Plan to resume clinical study and ensure safety by evaluating plasma and pharmacological biomarkers that can be used in the short term to assess and monitor safety₂₄



Progress in Morphotek[®]'s Antibody Pipeline



MORAb-003

- Monoclonal antibody targeting folate receptor alpha
- Phase II study for ovarian cancer ongoing
 - Platinum-sensitive recurrent ovarian cancer
 - Monotherapy and combination therapy with carboplatin + taxane
 - Target: 60 patients
 - Primary endpoint: length of remission

MORAb-009

- Monoclonal antibody targeting mesothelin
- Phase I study ongoing
- Preparing for Phase II study for pancreatic cancer (1st line)
 - MORAb-009 + gemcitabine vs. placebo + gemcitabine
 - Target: 152 patients (76 patients/arm)
 - Primary endpoint: survival time
 - Plan to initiate in 3Q FY2007
- Preparing for Phase II study for mesothelioma
 - Plan to initiate within FY2007





E7820

Alpha 2 Integrin
Expression Inhibitor
Colorectal Cancer

E7080VEGF Receptor
Tyrosine Kinase
Inhibitor

Cytotoxic E7389

Phase III

Phase II

Phase I











Additional Indication for Severe Alzheimer's Disease (AD)

 Received approval for additional efficacy and dosage for treatment of severe AD in Japan (August 23, 2007)

<Outline of the new indication>

For severe patients, administration should be started with 5 mg once daily, and after 4 weeks, the daily dose should be increased to 10 mg

<New formulation>

"Aricept® Tablet 10 mg", "Aricept® D Tablet 10 mg" (Available after price listing in December 2007)

 Worldwide approval status of severe AD U.S. (October 2006), Canada (June 2007) Australia (August 2007), New Zealand (March 2007) India (December 2006), Philippines (February 2007)





NME Pipeline
Enrichment in Late-Stage Projects: 10 Compounds in Phase III or Submitted

Phase II initiated in Japan